Ophthalmic Disease Therapeutics Market Size, Share, Growth Analysis, By Disease indication(Glaucoma, Retinal disease, Dry Eye Disease, Allergy & Infection), By Drug Class(Anti-Inflammatory, Anti – infective, Anti- VEGF, Anti Glaucoma), By Region - Industry Forecast 2024-2031

Ophthalmic Disease Therapeutics Market size was valued at USD 31.6 billion in 2019 and is poised to grow from USD 33.5 billion in 2023 to USD 53.8 billion by 2031, growing at a CAGR of 6.10% in the forecast period (2024-2031).

Given the steadily rising prevalence of ocular diseases globally and the increasing need for vision care and treatment is widely felt at a global scale. The National Eye Institute estimates that vision loss and vision diseases cost US$139 billion annually to the U.S. economy. The predicted expansion of the worldwide ophthalmic therapeutics market is largely due to the increased prevalence of blindness.

The major pharmaceutical companies are making significant investments in the research and development of novel therapies for the treatment of retinal disorders, and it is anticipated that more cutting-edge therapies will be approved in the upcoming years, propelling the growth of the ophthalmic disease therapeutics market. Additionally, the development of OTC (Over-the-Counter) therapeutics in Asian nations as a result of the introduction of affordable ocular drugs by local manufacturers is anticipated to increase the revenue generated by ophthalmic therapeutics in the global ophthalmic disease therapeutics market during the forecast period.

Anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and other medication classes are available on the market. Out of these, anti-inflammatory medications held a 27% market share for ocular disease therapies in 2019 and are anticipated to maintain their dominance over the forecast period. 

US Ophthalmic Disease Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.